Table 5. Stratified analyses of the difference hypotensive effects of α,β-ADR blockers between KCNH2 (1956,C>T) genotypes(CC v.s CT+TT) and age(≤55 y v.s 55 y), gender(Men v.s Women)interactions in EH patients.

Drugs	Genotype, Age and (or) Gender-Specific	variables	mean±S.D	P*-value
doxazosin	M-CC(15) v.s W-CC(13)	ΔDBP6	−13.7±8.3 v.s −0.1±8.6	0.003
		ΔMAP6	−14.7±8.9 v.s −1.9±9.8	0.019
bisoprol or atenolol	CC(34) v.s CT/TT(4)	ΔPP4	−0.8±11.8 v.s −14.0±3.8	0.030
doxazosin or celiprolol	M-CC(36) v.s W-CC(31);	ΔDBP6	−14.1±6.5 v.s −7.5±10.6	0.029
		ΔMAP6;	−15.0±6.9 v.s −8.0±10.4;	0.043 ;
	M-Age>55y-CC (26) v.s W-Age>55y-CC (13)	ΔDBP6	−14.8±4.9 v.s −2.1±11.2	0.004
		ΔMAP6	−15.7±5.3 v.s−3.7±11.2	0.027
doxzosin, bisoprolol or atenolol	Age≤55y-CC (47) v.s Age>55y-CC(47);	ΔHR4	−9.4±14.7 v.s0.7±11.6	0.015
		ΔDBP4	−18.6±10.2 v.s −11.9±8.5	0.008
	Age≤55y-M-CC(25) v.s Age>55y-M-CC(29)	ΔMAP;	−19.6±10.2 v.s −13.2±8.9;	0.029;
		ΔHR4	−9.6±13.6 v.s −2.5±10.9	0.031
cileprolol, bisoprolol or atenolol	Age≤55y-CC v.s Age>55y-CC	ΔDBP4	−20.3±9.3 v.s −13.8±8.2	0.017
		ΔMAP4	−20.7±9.3 v.s −15.0±8.7	0.047
doxazosin, cileprolol, bisoprolol or atenolol	Age≤55y-CC(65) v.s Age>55y-CC(69);	ΔHR4	−6.5±14.0 v.s 0.1±01.2	0.082
		ΔDBP4	−17.2±9.7 v.s−11.8±8.0	0.004
	M-Age≤55y-CC(30) v.s W-Age>55y-CC(24);	ΔMAP4;	−18.1±9.7 v.s−13.2±8.5;	0.023;
		ΔDBP4	18.2±9.7 v.s −10.4±9.0	0.017
	Age≤55y-M-CC(30) v.s Age>55y-M-CC(45)	ΔMAP	−19.4±9.2 v.s −11.9±9.7;	0.048;
		ΔHR4	−8.2±2.4 v.s 0.8±1.4	0.045

^*P-values were with bonferroni adjust and BMI, gender ,age adjust were appropriately use in the model,ΔHR4 = heart rate change at the end of 4 weeks, ΔDBP4 = diastolic pressure change at the at the end of 4 weeks,ΔMAP4 = mean arterial pressure change at the at the end of 4 weeks, ΔPP4 = pulse pressure change at the end of 4 weeks, ΔDBP6 = diastolic pressure change at the end of 6weeks, ΔMAP6 = mean arterial pressure change at the end of 6 weeks.